Strategies for Hormone Receptor-Positive Metastatic BC

OncLiveTV
21 Jan, 2020 ,

Hope S. Rugo and Joyce A. O’Shaughnessy discuss findings from the phase II Young-PEARL study from ASCO 2019 regarding the use of CDK4/6 inhibitors for hormone receptor-positive metastatic breast cancer and the use of chemotherapy in the frontline setting.